Company profilePharmaceutical#18 of 1,318 in Pakistan7 DRAP alerts

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.

Pharmaceutical company · 377 brands · 402 molecules

Ranked #9 of 70 companies in Cardiac Care

377 registered products 60 pharmaceutical brands 402 distinct molecules 7 DRAP alerts

Company overview

377
registered products
60
pharmaceutical brands
402
distinct molecules
12
therapeutic classes
7
DRAP alerts

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 377 product registrations across 402 distinct molecules. It is the 18th largest registrant in Pakistan by product count, and ranks 9th of 70 in Cardiac Care. Its portfolio is concentrated in Cardiac Care and Other Beta-Lactam, Cephalosporins & Penems. DRAP has issued 7 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by ZAFA

266 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

226
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
202512
2026213
Longest without revision

Top molecules by brand count

Eye12 brands
Amlodipine10 brands
Zinc6 brands
Artemether6 brands
Magnesium5 brands
Paracetamol5 brands
Amikacin5 brands

Therapeutic classes

Cardiac Care · 10Other Beta-Lactam, Cephalosporins & Penems · 9Antiinflammatory And Antirheumatic Products · 7Anti-Infective, Ophthalmologicals · 6Calcium Channel Blockers · 6Beta-Lactam Antibacterials, Penicillins · 6Quinolone Antibacterials · 6Hormone Regulators · 6Antimalarials · 5Drugs For Obstructive Airway Diseases, Systemic · 5Oestrogens · 4Blood Glucose Lowering Drugs, Excluding Insulin · 4

Conditions treated

Hypertension · 7Hormonal Therapy · 3Contraceptives · 3Nasal Congestion · 2Angina · 2Fungal Infection · 2Intestinal & Bowel Syndrome · 1Anxiety/Depression/Insomnia · 1Blood Clot/Thrombotic Disorder · 1Diarrhoea · 1High Cholestrol · 1Cold/Cough/Flu · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official272 products · Rs 12.19 – Rs 14,387.88
DVAGO22 products · Rs 30.4 – Rs 3,030.55
Servaid33 products · Rs 19.56 – Rs 995.2
Median across source: Rs 93.8

Regulatory record

7 alerts in the DRAP feed we track.

Suspension of marketing authorisations of 17-Hydroxyprogesterone caproate (17- OHPC) due t
2025-07-09
Recall Alert: RECALL OF PRODUCTS CONTAINING HYDROXYPROGESTERONE CAPROATE
2025-06-23
Recall Alert: Drug Product; Zaftolin 5mg/ml Solution by Zafa Pharmaceutical Pvt Ltd, Karac
2024-05-21
Drug Safety Alert: Risk of Serious Renal and Gastrointestinal Harms with Codeine plus Ibup
2023-10-26
Recall Alert: Drug Product; Hydralazine 25mg Tablets (Batch # 257) by M/s Zafa Pharmaceuti
2023-02-23
Recall Alert; Drug Product: Zatranex 50mg/mL injection (Batch # 622) by M/s. Zafa Pharmace
2022-10-06
Drug Product Recall: Zatranex Injection (Batch #594) By M/S. Zafa Pharmaceutical Laborator
2021-12-06

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Atco Pharma International (Pvt) Ltd holds 179 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAmlodipine 6.95Mg Amlodipine BaseAmlodipine,Atorvastatin Calcium
NEUTRO PHARMA (PVT) LTD. holds 84 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAnastrazoleAnastrozoleAntimony
Wilshire Laboratories (Private) Limited holds 87 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmoxycillinAmoxycillin BaseAnastrozole

Get the full profile for ZAFA

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.